Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2010 1
2011 1
2014 2
2015 1
2018 3
2019 5
2020 7
2021 9
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Llibre JM, et al. Among authors: galera c. Clin Infect Dis. 2023 Feb 18;76(4):720-729. doi: 10.1093/cid/ciac130. Clin Infect Dis. 2023. PMID: 35235656 Free PMC article. Clinical Trial.
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Clinical utility of maraviroc.
Parra J, Portilla J, Pulido F, Sánchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, Blanco JL, Domingo P, Dronda F, Galera C, Gutiérrez F, Kindelán JM, Knobel H, Leal M, López-Aldeguer J, Mariño A, Miralles C, Moltó J, Ortega E, Oteo JA. Parra J, et al. Among authors: galera c. Clin Drug Investig. 2011;31(8):527-542. doi: 10.2165/11590700-000000000-00000. Clin Drug Investig. 2011. PMID: 21595497 Review.
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.
Berenguer J, Díez C, Martín-Vicente M, Micán R, Pérez-Elías MJ, García-Fraile LJ, Vidal F, Suárez-García I, Podzamczer D, Del Romero J, Pulido F, Iribarren JA, Gutiérrez F, Poveda E, Galera C, Izquierdo R, Asensi V, Portilla J, López JC, Arribas JR, Moreno S, González-García J, Resino S, Jarrín I. Berenguer J, et al. Among authors: galera c. Clin Microbiol Infect. 2021 Nov;27(11):1678-1684. doi: 10.1016/j.cmi.2021.06.023. Epub 2021 Jun 26. Clin Microbiol Infect. 2021. PMID: 34186209 Free PMC article. Review.
Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice.
Gonzalez-Serna A, Corma-Gomez A, Tellez F, Corona-Mata D, Rios-Villegas MJ, Merino D, Galera C, Collado-Romacho AR, De Los Santos I, Cucurull J, Santos M, García-Martín S, Rivero A, Real LM, Macias J. Gonzalez-Serna A, et al. Among authors: galera c. J Antimicrob Chemother. 2023 Oct 3;78(10):2591-2596. doi: 10.1093/jac/dkad278. J Antimicrob Chemother. 2023. PMID: 37671831 Free PMC article.
Integrase inhibitors in children and adolescents: clinical use and resistance.
Torres-Fernandez D, Jiménez de Ory S, Fortuny C, Sainz T, Falcón D, Bernal E, Jiménez MC, Vilasaró MN, Epalza C, Navarro M, Ramos JT, Holguín Á, Prieto L; CoRIS and CoRISpe Spanish National Cohorts, CoRISpe and CoRISpe-FARO Cohort Working Group. Torres-Fernandez D, et al. J Antimicrob Chemother. 2022 Sep 30;77(10):2784-2792. doi: 10.1093/jac/dkac259. J Antimicrob Chemother. 2022. PMID: 35971971
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
Troya J, Dueñas C, Irazola I, de Los Santos I, de la Fuente S, Gil D, Hernández C, Galindo MJ, Gómez J, Delgado E, Moreno-García E, Pousada G, Aldámiz T, Iribarren JA, Guerra JM, Morán MÁ, Galera C, De La Fuente J, Peláez A, Cervero M, Garcinuño M, Montero M, Ceballos F, Buzón L; on behalf of the DORIPEX Study Group. Troya J, et al. Among authors: galera c. Medicine (Baltimore). 2022 Jun 17;101(24):e29252. doi: 10.1097/MD.0000000000029252. Medicine (Baltimore). 2022. PMID: 35713430 Free PMC article.
44 results